Compare
Bioharvest Sciences Inc. vs Verrica Pharmaceuticals Inc. vs Sunshine Biopharma Inc. vs Lftd Partners Inc.
| Latest fiscal year | Bioharvest Sciences Inc. BHST | Verrica Pharmaceuticals Inc. VRCA | Sunshine Biopharma Inc. SBFM | Lftd Partners Inc. LIFD |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $34.51M | $35.58M | $36.31M | $36.92M |
| Revenue growth (YoY) | +37.0% | +370.2% | +4.1% | -1.1% |
| Gross margin | 59.3% (computed) | n/a | 33.8% | 34.2% |
| Operating margin | -16.2% | -34.2% | -17.2% | 2.5% |
| Net margin | -32.3% | -50.3% | -16.5% | -67.3% |
| Net income | -$11.13M | -$17.89M | -$5.98M | -$24.86M |
| EPS (Diluted) | n/a | -$1.68 | n/a | -$1.68 |
| Operating cash flow | -$7.23M | -$17.63M | -$5.33M | $1.32M |
| Free cash flow | -$9.58M | -$17.63M | -$5.51M | $1.20M |
| Cash & equivalents | $23.02M | $30.15M | n/a | $1.77M |
| Total assets | n/a | $47.13M | $30.08M | $19.27M |
| Total liabilities | n/a | $22.39M | $7.04M | $6.64M |
| Shareholders' equity | $25.45M | $24.74M | $23.04M | $12.63M |
| Return on year-end equity | -43.8% | -72.3% | -25.9% | -196.8% |
| Shares outstanding | n/a | 17.18M | 4.91M | 14.82M |
Revenue, most recent five fiscal years
| Fiscal year | Bioharvest Sciences Inc. | Verrica Pharmaceuticals Inc. | Sunshine Biopharma Inc. | Lftd Partners Inc. |
|---|---|---|---|---|
| Latest | $34.51M Ended 2025-12-31 | $35.58M Ended 2025-12-31 | $36.31M Ended 2025-12-31 | $36.92M Ended 2025-12-31 |
| 1 year earlier | $25.19M Ended 2024-12-31 | $7.57M Ended 2024-12-31 | $34.87M Ended 2024-12-31 | $37.33M Ended 2024-12-31 |
| 2 years earlier | $12.67M Ended 2023-12-31 | $5.12M Ended 2023-12-31 | $24.09M Ended 2023-12-31 | $51.61M Ended 2023-12-31 |
| 3 years earlier | n/a | $9.03M Ended 2022-12-31 | $4.35M Ended 2022-12-31 | $57.42M Ended 2022-12-31 |
| 4 years earlier | n/a | $12.00M Ended 2021-12-31 | $228.4K Ended 2021-12-31 | $31.66M Ended 2021-12-31 |